Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

2025144 citationsJournal Articlegreen Open Access

Authors

Richard Furie · Northwell Health

Brad H. Rovin · The Ohio State University

Jay Garg

Mittermayer B. Santiago · Escola Bahiana de Medicina e Saúde Pública

Gustavo Aroca · Universidad Simón Bolívar

Adolfina Elizabeth Zuta Santillán

Dámaris Álvarez

Claudio Sandoval · Universidad Privada San Juan Bautista

Abstract

Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov number, NCT04221477.).

Topics & Keywords

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Liver Diseases and Immunity

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 392, Issue 15, pp. 1471-1483

DOI: 10.1056/nejmoa2410965

Field-Weighted Citation Impact: 240.65